Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) have been given a consensus rating of “Hold” by the nine analysts that are currently covering the firm, Marketbeat reports. Seven analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $30.6667.

LKFT has been the subject of several research analyst reports. Wall Street Zen lowered Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Morgan Stanley lowered their target price on Lakefront Biotherapeutics American Depositary Shares from $30.00 to $26.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 11th. TD Cowen initiated coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Friday, August 21st. They issued a “buy” rating for the company. Royal Bank Of Canada reduced their price objective on shares of Lakefront Biotherapeutics American Depositary Shares from $28.00 to $26.00 and set a “sector perform” rating for the company in a research report on Tuesday, August 11th. Finally, Weiss Ratings raised shares of Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, August 27th.

Institutional Investors Weigh In On Lakefront Biotherapeutics American Depositary Shares

A number of institutional investors and hedge funds have recently modified their holdings of LKFT. Ameriprise Financial Inc. raised its position in shares of Lakefront Biotherapeutics American Depositary Shares by 2,490.1% during the third quarter. Ameriprise Financial Inc. now owns 1,416,934 shares of the biotechnology company’s stock worth $49,083,000 after purchasing an additional 1,362,229 shares during the period. UBS Group AG increased its stake in Lakefront Biotherapeutics American Depositary Shares by 128.4% in the 4th quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock worth $11,427,000 after purchasing an additional 196,445 shares in the last quarter. Millennium Management LLC raised its holdings in Lakefront Biotherapeutics American Depositary Shares by 121.9% during the 4th quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock worth $11,097,000 after buying an additional 186,452 shares during the period. Jane Street Group LLC lifted its stake in Lakefront Biotherapeutics American Depositary Shares by 2,245.7% during the first quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock valued at $2,783,000 after buying an additional 115,946 shares in the last quarter. Finally, Kotler Kevin acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the fourth quarter worth about $2,943,000. Institutional investors and hedge funds own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Price Performance

NASDAQ LKFT opened at $28.49 on Friday. Lakefront Biotherapeutics American Depositary Shares has a 12 month low of $25.68 and a 12 month high of $37.78. The firm has a market capitalization of $1.88 billion, a PE ratio of -20.21 and a beta of 0.28. The company’s 50 day simple moving average is $28.72 and its 200 day simple moving average is $29.42.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its earnings results on Monday, August 10th. The biotechnology company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $1.01. The firm had revenue of $15.47 million during the quarter, compared to analyst estimates of $7.29 million. Sell-side analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -1.27 earnings per share for the current fiscal year.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.